This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
blood donors | 695 |
public health | 663 |
health care | 567 |
blood transfusion | 562 |
study design | 543 |
case studies | 531 |
background case | 481 |
whole blood | 456 |
blood components | 421 |
red blood | 417 |
design method | 387 |
results finding | 375 |
blood products | 357 |
health system | 350 |
blood donation | 338 |
red cell | 330 |
health systems | 303 |
blood bank | 299 |
machine learning | 282 |
blood cells | 279 |
transfusion medicine | 279 |
infectious diseases | 270 |
climate change | 261 |
united states | 251 |
blood group | 244 |
early warning | 235 |
infectious disease | 235 |
immune system | 227 |
blood cell | 214 |
red cells | 214 |
syndromic surveillance | 195 |
blood donor | 193 |
nucleic acid | 180 |
information systems | 178 |
platelet concentrates | 173 |
cord uid | 172 |
doc id | 172 |
social media | 170 |
transfusion service | 170 |
health information | 168 |
blood banks | 158 |
food system | 158 |
transfusion reactions | 156 |
blood center | 154 |
national health | 152 |
stem cell | 149 |
drug delivery | 148 |
blood units | 148 |
decision making | 146 |
flow cytometry | 145 |
results findings | 144 |
patient care | 144 |
may also | 144 |
health insurance | 143 |
oral health | 143 |
design methods | 142 |
gene expression | 139 |
food waste | 137 |
blood collection | 136 |
health research | 135 |
platelet count | 135 |
blood samples | 134 |
food production | 133 |
blood donations | 130 |
mass production | 130 |
patient safety | 128 |
significant difference | 127 |
social systems | 126 |
important role | 126 |
adverse events | 125 |
stem cells | 125 |
energy system | 122 |
food systems | 121 |
quality control | 120 |
bacterial contamination | 118 |
case study | 115 |
health services | 114 |
bone marrow | 114 |
indoor vertical | 113 |
performed using | 112 |
scoring system | 110 |
world health | 110 |
ep laboratory | 109 |
social tipping | 109 |
large number | 108 |
clinical trials | 108 |
artificial intelligence | 108 |
risk factors | 107 |
side effects | 106 |
risk assessment | 106 |
blood supply | 106 |
significantly higher | 103 |
blood product | 103 |
information system | 103 |
rbc units | 103 |
widely used | 103 |
immune response | 102 |
time series | 102 |
developing countries | 102 |
different types | 102 |
first time | 101 |
two different | 100 |
sample preparation | 100 |
statistically significant | 100 |
earth system | 100 |
iu ml | 100 |
vertical farms | 100 |
recent years | 100 |
surveillance systems | 99 |
wide range | 99 |
transfusion services | 99 |
human health | 98 |
acute respiratory | 97 |
mental health | 96 |
control group | 95 |
hbv dna | 94 |
disease surveillance | 94 |
blood safety | 93 |
respiratory syndrome | 93 |
pregnant women | 93 |
dental care | 92 |
amino acids | 92 |
disease outbreaks | 92 |
amino acid | 92 |
total number | 92 |
per year | 91 |
ai systems | 91 |
supply chain | 91 |
periodontal disease | 91 |
ai ethics | 90 |
health organization | 90 |
autologous blood | 90 |
blood loss | 90 |
high level | 88 |
care system | 88 |
real time | 87 |
medical care | 87 |
mg dl | 87 |
antiglobulin test | 87 |
results show | 87 |
two groups | 86 |
blood pressure | 86 |
blood component | 86 |
electronic health | 85 |
hcv rna | 84 |
delivery systems | 84 |
warning system | 84 |
significant differences | 84 |
blood services | 84 |
smart home | 83 |
proposed system | 83 |
nucleic acids | 83 |
information technology | 82 |
frozen plasma | 82 |
big data | 82 |
even though | 81 |
lymph nodes | 81 |
clinically significant | 81 |
present study | 81 |
population health | 81 |
ml systems | 81 |
rbc transfusion | 80 |
first step | 80 |
income countries | 80 |
positive samples | 79 |
medical center | 79 |
national blood | 78 |
complex systems | 78 |
severe acute | 78 |
systematic review | 78 |
time pcr | 78 |
factor viii | 78 |
blood centers | 78 |
peripheral blood | 77 |
responsive systems | 77 |
may lead | 77 |
per unit | 77 |
healthcare system | 77 |
delivery system | 76 |
biological systems | 75 |
escherichia coli | 75 |
room temperature | 75 |
management system | 75 |
primary care | 75 |
physical systems | 75 |
antibody screen | 75 |
intensive care | 74 |
positive results | 74 |
fresh frozen | 74 |
last years | 74 |
tipping processes | 74 |
smart contract | 74 |
clinical practice | 74 |
least one | 73 |
chain reaction | 73 |
production system | 73 |
commonly used | 73 |
polymerase chain | 73 |
patients undergoing | 73 |
sustainable development | 72 |
data analysis | 71 |
data collection | 71 |
platelet transfusion | 71 |
rfid technology | 70 |
systems biology | 70 |
transfusion practice | 70 |
see table | 69 |
surveillance system | 69 |
ecosystem services | 69 |
deep learning | 69 |
warning systems | 69 |
ng ml | 69 |
dental schools | 69 |
neural networks | 68 |
sustainability science | 68 |
antibody screening | 67 |
results showed | 67 |
large scale | 67 |
results obtained | 67 |
air conditioning | 67 |
information exchange | 66 |
blood volume | 66 |
mass spectrometry | 65 |
health outcomes | 65 |
blood banking | 65 |
years ago | 65 |
system will | 65 |
air quality | 65 |
university hospital | 65 |
early detection | 65 |
critically ill | 64 |
red cross | 64 |
assay system | 64 |
false positive | 64 |
ill patients | 63 |
cardiac surgery | 63 |
medical record | 63 |
production systems | 63 |
high quality | 63 |
tipping points | 63 |
risk management | 63 |
neural network | 63 |
gene therapy | 62 |
immune responses | 62 |
drug release | 62 |
food security | 62 |
test results | 62 |
global health | 62 |
silico modeling | 62 |
literature review | 61 |
blood groups | 61 |
results indicate | 61 |
blood service | 61 |
health status | 61 |
cell lines | 61 |
natural language | 61 |
will also | 61 |
systems approach | 61 |
healthcare systems | 60 |
massive transfusion | 60 |
transfusion therapy | 60 |
snow agent | 60 |
donate blood | 60 |
contact tracing | 60 |
cd cells | 60 |
public transport | 60 |
fully automated | 59 |
susceptibility testing | 59 |
european union | 59 |
years old | 59 |
new york | 59 |
case report | 59 |
direct antiglobulin | 59 |
year old | 59 |
buffy coat | 58 |
monoclonal antibodies | 58 |
learning systems | 58 |
antibody identification | 58 |
take place | 58 |
will require | 58 |
one hand | 58 |
system resilience | 57 |
based systems | 57 |
mathematical models | 57 |
water quality | 57 |
usable security | 57 |
molecular dynamics | 57 |
based approach | 56 |
uv light | 56 |
within hours | 56 |
ml based | 56 |
specific antibodies | 55 |
electronic medical | 55 |
protein synthesis | 55 |
lactic acid | 55 |
ventilation system | 55 |
plasma membrane | 55 |
will need | 55 |
social sciences | 55 |
donor selection | 54 |
quality improvement | 54 |
community health | 54 |
new technologies | 54 |
sickle cell | 54 |
national institute | 54 |
current state | 54 |
scansystem tm | 54 |
informed consent | 54 |
rhce ce | 54 |
high throughput | 54 |
voluntary blood | 54 |
innate immune | 54 |
cord blood | 53 |
health professionals | 53 |
fuzzy logic | 53 |
innovation system | 53 |
system may | 53 |
may occur | 52 |
health informatics | 52 |
information security | 52 |
high levels | 52 |
molecular weight | 52 |
class i | 52 |
clinical data | 52 |
many different | 52 |
long term | 52 |
statistical analysis | 51 |
molecular biology | 51 |
pathogen reduction | 51 |
small number | 51 |
causal closure | 51 |
drinking water | 51 |
health workers | 51 |
human factors | 51 |
lymphatic system | 51 |
data set | 51 |
platelets stored | 50 |
health record | 50 |
buffy coats | 50 |
biological system | 50 |
access control | 50 |
many countries | 50 |
transfusion reaction | 50 |
quality management | 50 |
three different | 50 |
quality assurance | 50 |
food safety | 50 |
increased risk | 50 |
based modeling | 50 |
pg ml | 50 |
health policy | 50 |
disease control | 50 |
care unit | 49 |
capillary electrophoresis | 49 |
cell types | 49 |
lymph node | 49 |
medical staff | 49 |
large numbers | 49 |
detection system | 49 |
abo rh | 49 |
results suggest | 49 |
data collected | 48 |
living cells | 48 |
monitoring system | 48 |
better understanding | 48 |
donor screening | 48 |
data sources | 48 |
using different | 48 |
data sets | 48 |
safe blood | 48 |
plt count | 47 |
chemical engineering | 47 |
systems medicine | 47 |
breast cancer | 47 |
learning system | 47 |
benefi ts | 47 |
commercially available | 47 |
health service | 47 |
system based | 47 |
living systems | 47 |
type ii | 47 |
general hospital | 47 |
microfluidic systems | 47 |
platelet products | 47 |
negative blood | 47 |
pathogen inactivation | 47 |
female donors | 47 |
industrial environment | 47 |
cancer cells | 47 |
age group | 46 |
fetal dna | 46 |
social networks | 46 |
hong kong | 46 |
regional blood | 46 |
european countries | 46 |
energy consumption | 46 |
systems may | 46 |
center background | 46 |
differential equations | 46 |
emergency department | 46 |
innovation systems | 46 |
trauma patients | 46 |
membrane proteins | 46 |
indoor air | 46 |
mathematical model | 46 |
antimicrobial susceptibility | 46 |
learning portal | 46 |
united nations | 46 |
also used | 46 |
experimental data | 45 |
social network | 45 |
must also | 45 |
infectious agents | 45 |
lateral flow | 45 |
hbv infection | 45 |
storage time | 45 |
high risk | 45 |
coronavirus disease | 45 |
high frequency | 45 |
hemolytic transfusion | 45 |
past years | 45 |
rapid detection | 45 |
universal health | 45 |
well known | 45 |
energy use | 45 |
social system | 45 |
additive solution | 45 |
bact alert | 45 |
higher level | 45 |
north carolina | 45 |
renewable energy | 45 |
user satisfaction | 44 |
health security | 44 |
ehr systems | 44 |
treated rbcs | 44 |
heart disease | 44 |
gel test | 44 |
developed countries | 44 |
resilient health | 44 |
th century | 44 |
natural ventilation | 44 |
general population | 44 |
times higher | 44 |
clinical samples | 44 |
will help | 44 |
data sharing | 44 |
adaptation strategies | 43 |
phase transition | 43 |
environmental conditions | 43 |
monoclonal anti | 43 |
plasma samples | 43 |
human body | 43 |
novel coronavirus | 43 |
lessons learned | 43 |
hla antibodies | 43 |
real world | 43 |
saccharomyces cerevisiae | 43 |
wide variety | 43 |
data management | 43 |
general practitioners | 43 |
system using | 43 |
blood centre | 43 |
birth weight | 43 |
gut microbiota | 43 |
global food | 42 |
indirect antiglobulin | 42 |
cfu ml | 42 |
knowledge base | 42 |
will allow | 42 |
system dynamics | 42 |
genomic dna | 42 |
human beings | 42 |
white blood | 42 |
dental education | 42 |
limited number | 42 |
group system | 42 |
low level | 42 |
home healthcare | 42 |
st century | 42 |
determine whether | 42 |
waste reduction | 42 |
tipping elements | 42 |
apheresis platelets | 42 |
positive dat | 42 |
per patient | 42 |
patients receiving | 42 |
may include | 42 |
hospital transfusion | 42 |
respiratory tract | 41 |
high degree | 41 |
health surveillance | 41 |
isothermal amplification | 41 |
relatively low | 41 |
new zealand | 41 |
significant antibodies | 41 |
may result | 41 |
desiccant cooling | 41 |
adaptive immune | 41 |
nervous system | 41 |
fresh air | 41 |
significantly lower | 41 |
biological processes | 40 |
takes place | 40 |
life cycle | 40 |
may provide | 40 |
many cases | 40 |
three main | 40 |
body weight | 40 |
growth rate | 40 |
will provide | 40 |
tipping point | 40 |
single donor | 40 |
previous studies | 40 |
donated blood | 40 |
cell proliferation | 40 |
i will | 40 |
system vulnerabilities | 40 |
signal transduction | 40 |
ep procedures | 40 |
new technology | 40 |
across different | 39 |
cps systems | 39 |
million people | 39 |
based models | 39 |
task force | 39 |
anti hpa | 39 |
blood establishments | 39 |
occupational health | 39 |
sir model | 39 |
medical education | 39 |
single molecule | 39 |
adverse reactions | 39 |
production process | 39 |
platelet pools | 39 |
solid phase | 39 |
one year | 39 |
research systems | 39 |
adverse effects | 39 |
allogeneic blood | 39 |
study period | 38 |
traditional farming | 38 |
table shows | 38 |
smart contracts | 38 |
hbc positive | 38 |
will lead | 38 |
blood type | 38 |
hb level | 38 |
different countries | 38 |
creative commons | 38 |
climate system | 38 |
ventilation systems | 38 |
complex system | 38 |
viral load | 38 |
dental insurance | 38 |
complex networks | 38 |
key role | 38 |
probability distribution | 38 |
time donors | 38 |
allows us | 38 |
agent system | 38 |
health authorities | 38 |
time period | 38 |
risk reduction | 38 |
free energy | 38 |
microfluidic device | 37 |
per day | 37 |
plasma units | 37 |
positive antibody | 37 |
platelet counts | 37 |
risk factor | 37 |
currently available | 37 |
object detection | 37 |
health records | 37 |
bacterial detection | 37 |
cell concentrates | 37 |
cooling system | 37 |
chronic diseases | 37 |
transfused patients | 37 |
standard deviation | 37 |
may cause | 37 |
global warming | 37 |
blood system | 37 |
system design | 37 |
life sciences | 37 |
refractive index | 37 |
ghg emissions | 37 |
gamma globulin | 37 |
naturally occurring | 37 |
working group | 37 |
patient samples | 37 |
best practices | 37 |
based system | 37 |
care delivery | 37 |
transfusion transmitted | 37 |
research system | 37 |
new approach | 37 |
low levels | 37 |
made available | 36 |
user interface | 36 |
metabolic engineering | 36 |
vaccination uptake | 36 |
animal models | 36 |
cell line | 36 |
quality system | 36 |
significant increase | 36 |
month period | 36 |
dna sequencing | 36 |
reference laboratory | 36 |
may require | 36 |
catheter ablation | 36 |
ankara university | 36 |
health promotion | 36 |
platelet kit | 36 |
units per | 36 |
tm platelet | 36 |
among others | 36 |
spatial resolution | 36 |
building blocks | 36 |
analysis using | 36 |
many people | 36 |
world bank | 36 |
future research | 36 |
rbc transfusions | 36 |
temporal resolution | 36 |
using two | 36 |
post transfusion | 36 |
transfusion safety | 35 |
social distancing | 35 |
significant impact | 35 |
disease transmission | 35 |
long time | 35 |
critical care | 35 |
often used | 35 |
significantly increased | 35 |
positive result | 35 |
bacterial screening | 35 |
technical university | 35 |
hemolytic anemia | 35 |
control systems | 35 |
cost savings | 35 |
closely related | 35 |
bacterial growth | 35 |
responsive system | 35 |
type i | 35 |
next step | 35 |
near future | 35 |
per month | 35 |
ecological systems | 35 |
pcr amplification | 35 |
cell membrane | 34 |
high titer | 34 |
patients received | 34 |
high resolution | 34 |
south africa | 34 |
regression analysis | 34 |
cell separator | 34 |
cardiovascular disease | 34 |
apheresis platelet | 34 |
help us | 34 |
rhd gene | 34 |
zika virus | 34 |
detection time | 34 |
emergency response | 34 |
enzyme treated | 34 |
population exposure | 34 |
natural systems | 34 |
carbon source | 34 |
also known | 34 |
natural environment | 34 |
cd cell | 34 |
domain knowledge | 34 |
cell disease | 34 |
cell surface | 34 |
monoclonal antibody | 34 |
system reliability | 34 |
fully integrated | 34 |
blood transfusions | 34 |
energy transfer | 34 |
significant reduction | 34 |
also important | 34 |
fog edge | 34 |
healthy donors | 34 |
pediatric patients | 34 |
ex vivo | 34 |
human rights | 34 |
protein expression | 34 |
short time | 34 |
patient population | 34 |
social learning | 33 |
lung injury | 33 |
mitigation strategies | 33 |
systems based | 33 |
authors declare | 33 |
conformational changes | 33 |
clinical trial | 33 |
latent space | 33 |
dna amplification | 33 |
ion channels | 33 |
severe thrombocytopenia | 33 |
retrospective study | 33 |
column agglutination | 33 |
influenza virus | 33 |
climate tipping | 33 |
cd cd | 33 |
cell count | 33 |
well established | 33 |
blood management | 33 |
platelet storage | 33 |
fi rst | 33 |
american college | 33 |
decision support | 33 |
transboundary crisis | 33 |
positive control | 33 |
patient data | 33 |
donor blood | 33 |
different levels | 33 |
open source | 33 |
use efficiency | 33 |
security measures | 33 |
two years | 33 |
viral inactivation | 33 |
free protein | 33 |
ml kg | 33 |
two main | 33 |
significantly different | 33 |
fi ndings | 33 |
reagent lots | 33 |
great potential | 32 |
storage period | 32 |
sensitivity analysis | 32 |
virtual reality | 32 |
may help | 32 |
surgical procedures | 32 |
growth factor | 32 |
acid amplification | 32 |
donor population | 32 |
time blood | 32 |
preliminary results | 32 |
enterprise system | 32 |
coagulation factors | 32 |
window period | 32 |
west nile | 32 |
dendritic cells | 32 |
healthcare professionals | 32 |
dynamical systems | 32 |
past decade | 32 |
epithelial cells | 32 |
collective action | 32 |
abo blood | 32 |
heart failure | 32 |
next generation | 32 |
data storage | 32 |
ehr system | 32 |
also provides | 32 |
fatty acids | 32 |
viral infection | 32 |
emerging infectious | 32 |
also observed | 32 |
staphylococcus aureus | 32 |
mean age | 32 |
economic development | 32 |
also found | 32 |
fluorescence microscopy | 32 |
blood screening | 32 |
wild type | 32 |
platelet quality | 32 |
power spectrum | 32 |
per capita | 32 |
biological activity | 32 |
natural resources | 31 |
high sensitivity | 31 |
chronic disease | 31 |
turnaround time | 31 |
disulfide bond | 31 |
american red | 31 |
viral rna | 31 |
data acquisition | 31 |
blood sample | 31 |
young people | 31 |
local food | 31 |
five years | 31 |
one another | 31 |
relatively high | 31 |
care providers | 31 |
operating system | 31 |
recent advances | 31 |
dynamics simulations | 31 |
microfluidic devices | 31 |
vital signs | 31 |
care systems | 31 |
carbon dioxide | 31 |
bacillus anthracis | 31 |
physical system | 31 |
negative effects | 31 |
global scale | 31 |
light light | 31 |
adult learning | 31 |
cell free | 31 |
therapeutic plasma | 31 |
decision makers | 31 |
alloimmune thrombocytopenia | 31 |
occupational diseases | 31 |
systems will | 31 |
policy makers | 31 |
three times | 31 |
fluorescence detection | 31 |
corrective actions | 31 |
mission controller | 31 |
higher levels | 31 |
food supply | 31 |
membrane protein | 31 |
insurance coverage | 30 |
hemolytic disease | 30 |
research institute | 30 |
surgery patients | 30 |
new information | 30 |
transcritical bifurcation | 30 |
diagnostic tests | 30 |
allowed us | 30 |
patient received | 30 |
van kampen | 30 |
citric acid | 30 |
will likely | 30 |
production disruption | 30 |
critical point | 30 |
hospital blood | 30 |
biological networks | 30 |
digital systems | 30 |
protein production | 30 |
rheumatoid arthritis | 30 |
much higher | 30 |
complex adaptive | 30 |
food industry | 30 |
low cost | 30 |
based care | 30 |
acid production | 30 |
nir light | 30 |
public transportation | 30 |
cell biology | 30 |
clinical decision | 30 |
dengue fever | 30 |
critical transitions | 30 |
rich plasma | 30 |
last two | 30 |
united kingdom | 30 |
social security | 30 |
economic systems | 30 |
radiation exposure | 30 |
general public | 30 |
lymphatic vessels | 30 |
one patient | 30 |
platelet concentration | 30 |
model systems | 30 |
measured using | 30 |
feedback loops | 30 |
plasma exchange | 30 |
system administrators | 30 |
fold higher | 30 |
patient blood | 30 |
based methods | 30 |
shelf life | 30 |
process control | 29 |
protein interactions | 29 |
next section | 29 |
growth factors | 29 |
transfusion vol | 29 |
one unit | 29 |
rural areas | 29 |
molecular mechanisms | 29 |
retrospective analysis | 29 |
crisis management | 29 |
third party | 29 |
raman spectroscopy | 29 |
scoping review | 29 |
extracellular matrix | 29 |
adult patients | 29 |
positive donors | 29 |
give rise | 29 |
one single | 29 |
increasing number | 29 |
improve patient | 29 |
lupus erythematosus | 29 |
medical records | 29 |
lower level | 29 |
hla class | 29 |
average number | 29 |
significantly reduced | 29 |
fermentation process | 29 |
clinical use | 29 |
year period | 29 |
ph values | 29 |
contaminant exposure | 29 |
large volume | 29 |
natural hazards | 29 |
serum albumin | 29 |
significant changes | 29 |
statistical physics | 29 |
intrusion detection | 29 |
model parameters | 29 |
iron deficiency | 29 |
future work | 29 |
iron depletion | 29 |
natural sciences | 29 |
czech republic | 29 |
several years | 29 |
cognitive distance | 29 |
response team | 29 |
universal access | 29 |
blood flow | 29 |
just one | 28 |
signifi cant | 28 |
adult education | 28 |
several studies | 28 |
high prevalence | 28 |
cell culture | 28 |
recombinant proteins | 28 |
donor samples | 28 |
parameter values | 28 |
iot devices | 28 |
tested using | 28 |
apheresis procedures | 28 |
based modelling | 28 |
fatty acid | 28 |
will increase | 28 |
th day | 28 |
informational landscape | 28 |
antibody tests | 28 |
medical devices | 28 |
automated system | 28 |
blood cultures | 28 |
vr system | 28 |
another example | 28 |
mean platelet | 28 |
clinical outcome | 28 |
system also | 28 |
cancer patients | 28 |
enzyme activity | 28 |
data will | 28 |
personal data | 28 |
analyzed using | 28 |
service delivery | 28 |
infection status | 28 |
monitoring systems | 28 |
treated cells | 28 |
cell transfusion | 28 |
environmental impact | 28 |
will continue | 28 |
different kinds | 28 |
platelet antigens | 28 |
logistic regression | 28 |
hcv infection | 28 |
standard operating | 28 |
central nervous | 28 |
one needs | 28 |
large amounts | 28 |
old individuals | 28 |
one must | 28 |
hiv aids | 28 |
done using | 28 |
internal medicine | 28 |
person detection | 28 |
lipid membranes | 28 |
ebola virus | 28 |
flow rate | 28 |
tested positive | 28 |
critical transition | 28 |
widely accepted | 27 |
system modeling | 27 |
new system | 27 |
media platforms | 27 |
disease outbreak | 27 |
another important | 27 |
reagent red | 27 |
flow cytometric | 27 |
two major | 27 |
binding sites | 27 |
clinical care | 27 |
family members | 27 |
social engineering | 27 |
limiting case | 27 |
molecules per | 27 |
sample size | 27 |
allergic reactions | 27 |
drug discovery | 27 |
human brain | 27 |
urban areas | 27 |
positive blood | 27 |
online monitoring | 27 |
recombinant protein | 27 |
antibiotic resistance | 27 |
myocardial infarction | 27 |
two types | 27 |
endothelial cells | 27 |
reported cases | 27 |
imperfect production | 27 |
disulfide bonds | 27 |
routine use | 27 |
national level | 27 |
platelet units | 27 |
scientific research | 27 |
haemolytic disease | 27 |
plasma derivates | 27 |
hpa antibodies | 27 |
mammalian cells | 27 |
antimicrobial resistance | 27 |
healthy individuals | 27 |
immune cells | 27 |
vertical farming | 27 |
two systems | 27 |
post irradiation | 27 |
human activities | 27 |
environmental change | 27 |
operating room | 27 |
north america | 27 |
system needs | 27 |
land use | 27 |
clinically relevant | 27 |
water use | 27 |
bacillus subtilis | 27 |
monte carlo | 27 |
molecular level | 27 |
patients treated | 27 |
virus infection | 27 |
time interval | 27 |
oxygen transfer | 27 |
negative results | 27 |
per rbc | 27 |
computer science | 27 |
better understand | 27 |
donor base | 27 |
every day | 27 |
airborne transmission | 27 |
starting point | 27 |
cell antigens | 26 |
rfid tag | 26 |
management systems | 26 |
immunization registries | 26 |
detection systems | 26 |
broad range | 26 |
warning signals | 26 |
system use | 26 |
industrialized countries | 26 |
light scattering | 26 |
significant effect | 26 |
acute lung | 26 |
comparative study | 26 |
platelet transfusions | 26 |
laboratory testing | 26 |
mg kg | 26 |
potential benefits | 26 |
single cell | 26 |
identifi ed | 26 |
three years | 26 |
sensor network | 26 |
mainly due | 26 |
will take | 26 |
also performed | 26 |
federal government | 26 |
waste management | 26 |
also provide | 26 |
single unit | 26 |
platelet yield | 26 |
comparative analysis | 26 |
system must | 26 |
integral part | 26 |
mean value | 26 |
human genome | 26 |
input data | 26 |
issues related | 26 |
agricultural innovation | 26 |
work together | 26 |
response rate | 26 |
related diseases | 26 |
pluripotent stem | 26 |
medical schools | 26 |
cell units | 26 |
based techniques | 26 |
solid state | 26 |
medical history | 26 |
lactate dehydrogenase | 26 |
development goals | 26 |
pcr system | 26 |
mechanical ventilation | 26 |
sis model | 26 |
team members | 26 |
diseased tissues | 26 |
disease detection | 26 |
security policy | 26 |
methods used | 26 |
diabetes mellitus | 26 |
world war | 26 |
microfluidic chip | 26 |
energy storage | 26 |
time window | 26 |
blood collected | 26 |
time consuming | 26 |
relative humidity | 26 |
atrial fibrillation | 26 |
fuzzy inference | 26 |
major role | 26 |
based approaches | 25 |
sharing system | 25 |
ecological economics | 25 |
detection using | 25 |
carbon energy | 25 |
seroconversion panels | 25 |
nitrous oxide | 25 |
one example | 25 |
raw data | 25 |
systems thinking | 25 |
short period | 25 |
software engineering | 25 |
respiratory distress | 25 |
information quality | 25 |
packed red | 25 |
volume reduction | 25 |
final product | 25 |
extremely rare | 25 |
cd expression | 25 |
mg ml | 25 |
proposed architecture | 25 |
different methods | 25 |
human development | 25 |
one way | 25 |
related complications | 25 |
automated systems | 25 |
information regarding | 25 |
become increasingly | 25 |
publicly available | 25 |
knowledge bases | 25 |
built environment | 25 |
conditioning system | 25 |
binding site | 25 |
best practice | 25 |
iron stores | 25 |
sensor placement | 25 |
bacterial infections | 25 |
readily available | 25 |
ventilation rate | 25 |
widespread use | 25 |
effective treatment | 25 |
cardiovascular diseases | 25 |
great interest | 25 |
nile virus | 25 |
economic growth | 25 |
system level | 25 |
units transfused | 25 |
neonatal alloimmune | 25 |
i ii | 25 |
system allows | 25 |
may serve | 25 |
experimental results | 25 |
communication systems | 25 |
viral infections | 25 |
lipid bilayers | 25 |
host cell | 25 |
alkaline phosphatase | 25 |
thermal lens | 25 |
lipid bilayer | 25 |
health monitoring | 25 |
care costs | 25 |
environmental factors | 25 |
two decades | 25 |
early stages | 25 |
programmable logic | 24 |
ablation procedures | 24 |
statistical significance | 24 |
analysis showed | 24 |
silico models | 24 |
reporting system | 24 |
water supply | 24 |
heart rate | 24 |
global sustainability | 24 |
innovation policy | 24 |
medical practice | 24 |
middle east | 24 |
power supply | 24 |
psychological stress | 24 |
rbc antigens | 24 |
based model | 24 |
omics data | 24 |
study showed | 24 |
ml system | 24 |
control system | 24 |
political economy | 24 |
false positives | 24 |
effective use | 24 |
first two | 24 |
platelet components | 24 |
system analysis | 24 |
se bond | 24 |
cell separators | 24 |
major challenge | 24 |
tipping dynamics | 24 |
taken together | 24 |
pall ebds | 24 |
old female | 24 |
skeletal muscle | 24 |
fibrin glue | 24 |
social change | 24 |
outbreak detection | 24 |
inference system | 24 |
confirmed positive | 24 |
donor cells | 24 |
system security | 24 |
data points | 24 |
target protein | 24 |
host disease | 24 |
ferritin levels | 24 |
time spent | 24 |
negatively charged | 24 |
donor recruitment | 24 |
low frequency | 24 |
direct contact | 24 |
transfusion center | 24 |
different ways | 24 |
positive donations | 24 |
rhd negative | 24 |
adaptive systems | 24 |
data entry | 24 |
positive rate | 24 |
plasma volume | 24 |
aspergillus niger | 24 |
ph value | 24 |
systemic risks | 24 |
ultrio assay | 24 |
rational design | 24 |
air pollution | 24 |
see also | 24 |
technical systems | 24 |
recent study | 24 |
clinical settings | 24 |
risk analysis | 24 |
peer review | 24 |
mathematical modeling | 24 |
operating procedures | 24 |
end users | 24 |
risks associated | 24 |
serious adverse | 24 |
clinical studies | 24 |
emergency preparedness | 24 |
human serum | 24 |
human immunodeficiency | 24 |
detection limit | 24 |
provide information | 24 |
social science | 24 |
energy systems | 24 |
will present | 24 |
data suggest | 24 |
human resources | 24 |
recent studies | 24 |
seir model | 24 |
us department | 24 |
thalassemic patients | 24 |
new method | 24 |
allow us | 24 |
network analysis | 23 |
three types | 23 |
studies showed | 23 |
system failure | 23 |
service quality | 23 |
solid tumors | 23 |
tumor cells | 23 |
battery management | 23 |
systemic lupus | 23 |
clinical research | 23 |
rh typing | 23 |
integrated approach | 23 |
system performance | 23 |
medical data | 23 |
data processing | 23 |
marshfi eld | 23 |
transfusion related | 23 |
particle size | 23 |
heat recovery | 23 |
informal digital | 23 |
one study | 23 |
human organoids | 23 |
mass transfer | 23 |
conceptual framework | 23 |
high dose | 23 |
health inequalities | 23 |
also tested | 23 |
metabolic syndrome | 23 |
tested negative | 23 |
specific knowledge | 23 |
blood derived | 23 |
ml per | 23 |
negative impacts | 23 |
cobe spectra | 23 |
application layer | 23 |
work life | 23 |
proposed model | 23 |
much less | 23 |
new automated | 23 |
nan doi | 23 |
fossil fuels | 23 |
cell wall | 23 |
important aspect | 23 |
human society | 23 |
male donors | 23 |
population size | 23 |
single nucleotide | 23 |
energy efficiency | 23 |
differ significantly | 23 |
vertical farm | 23 |
leading indicators | 23 |
back pain | 23 |
supply chains | 23 |
time step | 23 |
processing time | 23 |
protein structure | 23 |
bike sharing | 23 |
compatible blood | 23 |
results indicated | 23 |
pulmonary edema | 23 |
production processes | 23 |
civil society | 23 |
may affect | 23 |
blood grouping | 23 |
detection methods | 23 |
decision analysis | 23 |
data analytics | 23 |
control samples | 23 |
low risk | 23 |
platelet refractoriness | 23 |
laboratory tests | 23 |
every year | 23 |
enveloped viruses | 23 |
mobile application | 23 |
ethnic groups | 23 |
second step | 23 |
human life | 23 |
optimal solution | 23 |
chronic conditions | 23 |
local level | 23 |
care facilities | 23 |
computer system | 23 |
per person | 23 |
taking advantage | 23 |
derived organoids | 23 |
interaction networks | 23 |
transmitted infections | 23 |
well tolerated | 22 |
training data | 22 |
htlv i | 22 |
speech recognition | 22 |
spatial scales | 22 |
blood bags | 22 |
high cost | 22 |
sample volume | 22 |
rhd genotyping | 22 |
mutual information | 22 |
operating costs | 22 |
major challenges | 22 |
vast majority | 22 |
expression data | 22 |
two methods | 22 |
see chapter | 22 |
days post | 22 |
high affinity | 22 |
extreme events | 22 |
data obtained | 22 |
summer monsoon | 22 |
evaluated using | 22 |
conscious sedation | 22 |
iron metabolism | 22 |
operating conditions | 22 |
low hb | 22 |
conditioning systems | 22 |
following sections | 22 |
ep laboratories | 22 |
agricultural systems | 22 |
old male | 22 |
four different | 22 |
atomic force | 22 |
different systems | 22 |
molecular methods | 22 |
cell growth | 22 |
samples tested | 22 |
linear regression | 22 |
among patients | 22 |
acid sequence | 22 |
donating blood | 22 |
genetically modified | 22 |
high incidence | 22 |
manual tube | 22 |
future studies | 22 |
white cell | 22 |
bus stops | 22 |
university school | 22 |
health problems | 22 |
significant role | 22 |
global climate | 22 |
international health | 22 |
critical role | 22 |
patient information | 22 |
two days | 22 |
slow system | 22 |
health data | 22 |
case reports | 22 |
mean hb | 22 |
one might | 22 |
nasal vaccine | 22 |
clinical setting | 22 |
seed value | 22 |
hydrophobic interaction | 22 |
will show | 22 |
median age | 22 |
transfusion testing | 22 |
new insights | 22 |
collected data | 22 |
deferred donors | 22 |
vice versa | 22 |
age groups | 22 |
present work | 22 |
based detection | 22 |
health facilities | 22 |
sustainability transitions | 22 |
healthcare industry | 22 |
anomaly detection | 22 |
mediated isothermal | 22 |
particularly important | 22 |
system quality | 22 |
acid testing | 22 |
also help | 22 |
health coverage | 22 |
platelet function | 22 |
irradiated blood | 22 |
tract infection | 22 |
various types | 22 |
two samples | 22 |
suspected cases | 22 |
plasma fractionation | 22 |
health officials | 22 |
vaccine delivery | 22 |
medical students | 22 |
platelet concentrate | 22 |
data security | 22 |
provider performance | 22 |
donor deferrals | 22 |
economic system | 22 |
deferral rates | 22 |
energy sources | 22 |
gut microbiome | 22 |
force microscopy | 22 |
microfluidic system | 22 |
immunodeficiency virus | 21 |
contamination risk | 21 |
computational models | 21 |
quality assessment | 21 |
system models | 21 |
antibiotic susceptibility | 21 |
flow rates | 21 |
weeks gestation | 21 |
magnetic cards | 21 |
health departments | 21 |
mac addresses | 21 |
mixed reality | 21 |
failed machines | 21 |
clinical impact | 21 |
minimum viable | 21 |
developing world | 21 |
hcv antibodies | 21 |
pharmaceutical industry | 21 |
standard methods | 21 |
nat screening | 21 |
anticancer drugs | 21 |
mayo clinic | 21 |
summary conclusions | 21 |
transfusion policy | 21 |
positive effect | 21 |
large amount | 21 |
lower levels | 21 |
confidence interval | 21 |
interaction design | 21 |
based transfusion | 21 |
predonation hb | 21 |
security mechanisms | 21 |
excessive bleeding | 21 |
among different | 21 |
cde cde | 21 |
yeast extract | 21 |
climate network | 21 |
disease diagnosis | 21 |
transcription factor | 21 |
smart grid | 21 |
blood culture | 21 |
identifi cation | 21 |
cell migration | 21 |
managed care | 21 |
acute care | 21 |
indian summer | 21 |
drug administration | 21 |
urinary tract | 21 |
blockchain database | 21 |
may vary | 21 |
existing systems | 21 |
shape model | 21 |
phase transitions | 21 |
primed donor | 21 |
true positive | 21 |
drug targets | 21 |
mobile phones | 21 |
living organisms | 21 |
allogenic blood | 21 |
technological learning | 21 |
industrial control | 21 |
reinforcement learning | 21 |
agglutination technology | 21 |
mission specification | 21 |
testing methods | 21 |
investigation system | 21 |
transfusion recipients | 21 |
human behavior | 21 |
abo group | 21 |
two weeks | 21 |
also possible | 21 |
dna sequences | 21 |
human disease | 21 |
making process | 21 |
laboratory systems | 21 |
autoimmune hemolytic | 21 |
rhd gamma | 21 |
useful tool | 21 |
key factor | 21 |
health needs | 21 |
carrying capacity | 21 |
surface area | 21 |
fluorescence spectroscopy | 21 |
health agencies | 21 |
different parts | 21 |
production cost | 21 |
alert system | 21 |
may become | 21 |
body temperature | 21 |
iiot architecture | 21 |
donor center | 21 |
last decade | 21 |
post office | 21 |
systems theory | 21 |
type diabetes | 21 |
adverse reaction | 21 |
rbc unit | 21 |
factors affecting | 21 |
gel electrophoresis | 21 |
stimulus responsive | 21 |
storage capacity | 21 |
cohort study | 21 |
life expectancy | 21 |
health problem | 21 |
model system | 21 |
vista tm | 21 |
infected individuals | 21 |
objective functions | 21 |
nasal cavity | 21 |
russian federation | 21 |
much lower | 21 |
musculoskeletal conditions | 21 |
financial crisis | 21 |
information sharing | 21 |
transfusion practices | 21 |
reachable sets | 21 |
heavy metals | 21 |
downward causation | 21 |
viable system | 21 |
time monitoring | 21 |
respiratory infections | 21 |
results demonstrate | 21 |
compatible platelets | 21 |
reverse transcription | 21 |
vr systems | 21 |
genetic algorithm | 21 |
medical school | 21 |
one case | 21 |
medical treatment | 21 |
correlation spectroscopy | 21 |
software development | 21 |
medium composition | 20 |
reactive oxygen | 20 |
within min | 20 |
system size | 20 |
dna extraction | 20 |
conceptual model | 20 |
bottom line | 20 |
bacterial culture | 20 |
changing conditions | 20 |
functional analysis | 20 |
systems science | 20 |
following transfusion | 20 |
also called | 20 |
flow cytometer | 20 |
billion people | 20 |
cell adhesion | 20 |
adverse event | 20 |
sensor networks | 20 |
gamma irradiation | 20 |
infection control | 20 |
point cloud | 20 |
network inference | 20 |
communication technologies | 20 |
mobility ride | 20 |
magnetic field | 20 |
expression levels | 20 |
higher education | 20 |
new public | 20 |
optimization problem | 20 |
magnetic beads | 20 |
higher prevalence | 20 |
test result | 20 |
public opinion | 20 |
caucasian population | 20 |
care needs | 20 |
private health | 20 |
carbon emissions | 20 |
five days | 20 |
vitro quality | 20 |
young children | 20 |
three levels | 20 |
cell transplantation | 20 |
intercept blood | 20 |
future directions | 20 |
ad hoc | 20 |
sea level | 20 |
mycobacterium tuberculosis | 20 |
culture conditions | 20 |
dna analysis | 20 |
term resilience | 20 |
stochastic infection | 20 |
many years | 20 |
pregnant woman | 20 |
metabolic pathways | 20 |
clinical information | 20 |
industrial internet | 20 |
rhd exons | 20 |
avian influenza | 20 |
healthy people | 20 |
different blood | 20 |
transfusion protocol | 20 |
co emissions | 20 |
erythrocyte antibodies | 20 |
pathogenic bacteria | 20 |
residual risk | 20 |
human plasma | 20 |
human cells | 20 |
three months | 20 |
conversational search | 20 |
two categories | 20 |
deep neural | 20 |
dental coverage | 20 |
lung cancer | 20 |
van der | 20 |
focus group | 20 |
air flow | 20 |
extreme rainfall | 20 |
communicable diseases | 20 |
systems using | 20 |
testing using | 20 |
simex materials | 20 |
rbc products | 20 |
false negative | 20 |
cell yield | 20 |
heart rhythm | 20 |
environmental protection | 20 |
transmitted diseases | 20 |
multiplex pcr | 20 |
using various | 20 |
will become | 20 |
computational cost | 20 |
response time | 20 |
studied using | 20 |
based ast | 20 |
western blot | 20 |
health sector | 20 |
home appliances | 20 |
serum ferritin | 20 |
inventory management | 20 |
communicating stream | 20 |
hiv positive | 20 |
systems use | 20 |
biomedical research | 20 |
group antigens | 20 |
oxygen species | 20 |
analytical sensitivity | 20 |
system uses | 20 |
system provides | 20 |
patients suffering | 20 |
gold nanoparticles | 20 |
repeat blood | 20 |
new challenges | 20 |
patient record | 20 |
scd patients | 20 |
three patients | 20 |
management strategies | 20 |
human population | 20 |
health emergencies | 20 |
much better | 20 |
cell antibodies | 20 |
european commission | 20 |
retrospective review | 20 |
plasma products | 20 |
listening post | 20 |
detailed information | 20 |
system might | 20 |
crucial role | 20 |
pollution events | 20 |
use cases | 19 |
emergency blood | 19 |
magnetic resonance | 19 |
coronary artery | 19 |
simulation runs | 19 |
storage lesion | 19 |
responsive drug | 19 |
blood establishment | 19 |
system complexity | 19 |
cd deficiency | 19 |
virtual robot | 19 |
optimal sensor | 19 |
low ph | 19 |
oriented software | 19 |
routinely used | 19 |
care services | 19 |
restrictive transfusion | 19 |
circular dichroism | 19 |
virus disease | 19 |
hematopoietic stem | 19 |
predictive value | 19 |
also includes | 19 |
central air | 19 |
based contact | 19 |
hospitalized patients | 19 |
performance evaluation | 19 |
obtained using | 19 |
circulatory overload | 19 |
normal rhd | 19 |
intended use | 19 |
economic impact | 19 |
one day | 19 |
fluorescence correlation | 19 |
south african | 19 |
mobile app | 19 |
product quality | 19 |
biotic impoverishment | 19 |
months later | 19 |
urgent need | 19 |
randomized controlled | 19 |
platelet aggregation | 19 |
free fetal | 19 |
business model | 19 |
physiological parameters | 19 |
related issues | 19 |
ethical issues | 19 |
first case | 19 |
previously described | 19 |
component therapy | 19 |
apheresis procedure | 19 |
transfusion trigger | 19 |
hyaluronic acid | 19 |
genome sequencing | 19 |
leucocyte depleted | 19 |
health sciences | 19 |
service provider | 19 |
positive cells | 19 |
cell death | 19 |
protein interaction | 19 |
will result | 19 |
transfusion centers | 19 |
important factor | 19 |
current study | 19 |
tipping process | 19 |
hospital based | 19 |
information available | 19 |
radio frequency | 19 |
previously reported | 19 |
final concentration | 19 |
see ref | 19 |
global environmental | 19 |
upper respiratory | 19 |
coagulation factor | 19 |
gold standard | 19 |
genetic engineering | 19 |
cancer cell | 19 |
manufacturing process | 19 |
digital computers | 19 |
platelet additive | 19 |
ebola outbreak | 19 |
rna detection | 19 |
olfactory system | 19 |
virus load | 19 |
given time | 19 |
sensitive systems | 19 |
embryonic stem | 19 |
family therapy | 19 |
physiological conditions | 19 |
simultaneous detection | 19 |
initial conditions | 19 |
human diseases | 19 |
information management | 19 |
sensitive data | 19 |
clinical status | 19 |
dna typing | 19 |
potassium level | 19 |
mobile phone | 19 |
shear stress | 19 |
canadian blood | 19 |
premature infants | 19 |
life threatening | 19 |
cellular processes | 19 |
health crisis | 19 |
platelet inventory | 19 |
pivotal role | 19 |
inventory system | 19 |
human error | 19 |
provides information | 19 |
scientific knowledge | 19 |
hybrid rhesus | 19 |
system used | 19 |
molecular testing | 19 |
plt transfusions | 19 |
patients without | 19 |
image analysis | 19 |
least squares | 19 |
potential risk | 19 |
system control | 19 |
paradigm shift | 19 |
design flaws | 19 |
west africa | 19 |
transmissible infections | 19 |
last decades | 19 |
bird flu | 19 |
systems analysis | 19 |
environmental impacts | 19 |
open access | 19 |
single point | 19 |
exchange transfusion | 19 |
rare blood | 19 |
least two | 19 |
bottle type | 19 |
protective measures | 19 |
relatively small | 19 |
thrombocytopenic patients | 19 |
visual analysis | 19 |
focus groups | 19 |
system development | 19 |
use case | 18 |
patient monitoring | 18 |
antigen presentation | 18 |
critical information | 18 |
closed system | 18 |
model membranes | 18 |
complex biological | 18 |
added value | 18 |
process time | 18 |
whole system | 18 |
time scale | 18 |
benefi ciaries | 18 |
undetected pollution | 18 |
convolutional neural | 18 |
selectin expression | 18 |
will make | 18 |
model based | 18 |
previous work | 18 |
recovery time | 18 |
six months | 18 |
th centile | 18 |
assessed using | 18 |
pancreatic cancer | 18 |
leukocyte antibodies | 18 |
mortality rates | 18 |
enzymatic activity | 18 |
international organizations | 18 |
significant decrease | 18 |
information processing | 18 |
dna microarrays | 18 |
local blood | 18 |
febrile illness | 18 |
study shows | 18 |
learning algorithms | 18 |
neurodegenerative diseases | 18 |
create new | 18 |
stored rbcs | 18 |
rhd positive | 18 |
inventory model | 18 |
portal success | 18 |
air volume | 18 |
endemic equilibrium | 18 |
regime shifts | 18 |
low back | 18 |
research council | 18 |
haemolytic anaemia | 18 |
spread spectrum | 18 |
useful information | 18 |
public policy | 18 |
western pacific | 18 |
preoperative autologous | 18 |
biological information | 18 |
mortality rate | 18 |
cps security | 18 |
ionizing radiation | 18 |
two additional | 18 |
laboratory information | 18 |
aggressive periodontitis | 18 |
disaster management | 18 |
blood circulation | 18 |
surface plasmon | 18 |
global population | 18 |
new disease | 18 |
global level | 18 |
powerful tool | 18 |
regulatory requirements | 18 |
production rate | 18 |
method using | 18 |
genes involved | 18 |
developed using | 18 |
last year | 18 |
real data | 18 |
infectious individuals | 18 |
ml min | 18 |
screening test | 18 |
evidence base | 18 |
tumor microenvironment | 18 |
rare donor | 18 |
ns ns | 18 |
improve health | 18 |
viral loads | 18 |
inh titre | 18 |
different conditions | 18 |
blockchain network | 18 |
outcome review | 18 |
city center | 18 |
mechanical properties | 18 |
normal tissues | 18 |
dna microarray | 18 |
clinical outcomes | 18 |
dynamical system | 18 |
systems transformation | 18 |
may even | 18 |
tertiary care | 18 |
normal range | 18 |
genetic studies | 18 |
rbc collection | 18 |
dna polymerase | 18 |
high performance | 18 |
medical device | 18 |
clinical situations | 18 |
regulatory networks | 18 |
new ways | 18 |
local health | 18 |
health emergency | 18 |
manufacturing processes | 18 |
new data | 18 |
intrauterine transfusions | 18 |
scada systems | 18 |
generate new | 18 |
examples include | 18 |
cell panel | 18 |
wet market | 18 |
partial ds | 18 |
donor platelets | 18 |
wt wt | 18 |
monolisa hcv | 18 |
high school | 18 |
related information | 18 |
sentence simplification | 18 |
augmented reality | 18 |
signifi cantly | 18 |
cell imaging | 18 |
healthcare data | 18 |
local population | 18 |
highly sensitive | 18 |
patient records | 18 |
system scales | 18 |
per week | 18 |
experiments showed | 18 |
recently reported | 18 |
positive reactions | 18 |
learning models | 18 |
cold storage | 18 |
operative infections | 18 |
size distribution | 18 |
gambro bct | 18 |
important information | 18 |
hemoglobin levels | 18 |
spreadsheet program | 18 |
air temperature | 18 |
support system | 18 |
one hour | 18 |
standard deviations | 18 |
platelet rich | 18 |
also play | 18 |
optimised scansystem | 18 |
lst system | 18 |
igg molecules | 18 |
dtt treatment | 18 |
transfusion hepatitis | 18 |
patient outcomes | 18 |
care professionals | 18 |
governance system | 18 |
study will | 18 |
care testing | 18 |
conversational systems | 18 |
patients requiring | 18 |
probably due | 18 |
diagnostic tools | 18 |
health safety | 18 |
hadley cell | 18 |
samples obtained | 18 |
group systems | 18 |
analysis system | 18 |
human populations | 18 |
antigen negative | 18 |
taking place | 18 |
autovue innova | 18 |
primary healthcare | 18 |
optimal control | 18 |
taken place | 18 |
data integration | 18 |
collect data | 18 |
repeat donors | 18 |
surface antigen | 18 |
older people | 18 |
yeast cells | 18 |
user vr | 18 |
power system | 18 |
great deal | 18 |
approach based | 18 |
microfluidic channel | 18 |
factors associated | 18 |
special attention | 18 |
measurement system | 18 |
procleix ultrio | 18 |
systems research | 18 |
homologous blood | 18 |
health issues | 18 |
galactosidase enzyme | 18 |
early childhood | 18 |
transfusion strategy | 18 |
volunteer donors | 18 |
antibody detection | 18 |
reachable set | 18 |
culture medium | 18 |
higher risk | 18 |
etas model | 18 |
determined using | 18 |
oral cavity | 17 |
extremely low | 17 |
eld clinic | 17 |
carbon sources | 17 |
global change | 17 |
many ways | 17 |
may involve | 17 |
public goods | 17 |
many studies | 17 |
analysis methods | 17 |
higher sensitivity | 17 |
competing interests | 17 |
emerging technologies | 17 |
private sector | 17 |
emergency management | 17 |
serologic testing | 17 |
maternal plasma | 17 |
research project | 17 |
systems used | 17 |
pilot study | 17 |
health expenditures | 17 |
clinical management | 17 |
prospective study | 17 |
apheresis donors | 17 |
greenhouse gas | 17 |
tube method | 17 |
give blood | 17 |
disease prevention | 17 |
nitrobenzyl group | 17 |
common good | 17 |
national guidelines | 17 |
infl ammatory | 17 |
rejuvenation solution | 17 |
may need | 17 |
four main | 17 |
hospital background | 17 |
data generated | 17 |
natural disasters | 17 |
well documented | 17 |
farming systems | 17 |
metal ions | 17 |
copies ml | 17 |
phosphatase enzyme | 17 |
well understood | 17 |
hydrogen bonds | 17 |
rhd beadchip | 17 |
plasma replacement | 17 |
gp clinics | 17 |
well suited | 17 |
early warnings | 17 |
replacement donors | 17 |
expert consensus | 17 |
relatively simple | 17 |
high concentration | 17 |
war ii | 17 |
individual patient | 17 |
may contain | 17 |
two units | 17 |
antibiotic therapy | 17 |
ascorbic acid | 17 |
systems need | 17 |
titer anti | 17 |
donor plasma | 17 |
national laboratory | 17 |
may contribute | 17 |
human well | 17 |
new methods | 17 |
relevant information | 17 |
derived platelets | 17 |
south carolina | 17 |
global economy | 17 |
young patients | 17 |
additional file | 17 |
fog computing | 17 |
many areas | 17 |
results will | 17 |
service providers | 17 |
academic medical | 17 |
related acute | 17 |
parking lot | 17 |
sexually transmitted | 17 |
two sets | 17 |
cancer treatment | 17 |
national research | 17 |
complement activation | 17 |
serological testing | 17 |
people living | 17 |
plasmon resonance | 17 |
group ab | 17 |
another way | 17 |
oxidative stress | 17 |
gain access | 17 |
data privacy | 17 |
three categories | 17 |
south america | 17 |
abo typing | 17 |
one month | 17 |
microfluidic channels | 17 |
especially important | 17 |
individual level | 17 |
system strengthening | 17 |
different forms | 17 |
time point | 17 |
umbilical cord | 17 |
transfusion committee | 17 |
hemoglobin level | 17 |
also need | 17 |
differential equation | 17 |
acid bacteria | 17 |
mononuclear cells | 17 |
bond energy | 17 |
febrile non | 17 |
two patients | 17 |
avian flu | 17 |
syndrome coronavirus | 17 |
dengue virus | 17 |
chemical analysis | 17 |
intravenous immunoglobulin | 17 |
human interventions | 17 |
polyethylene glycol | 17 |
blood ordering | 17 |
artificial neural | 17 |
studies using | 17 |
safety measures | 17 |
fold increase | 17 |
clinical diagnostics | 17 |
two cases | 17 |
machine repair | 17 |
south korea | 17 |
hbv nat | 17 |
binding proteins | 17 |
working conditions | 17 |
infected people | 17 |
adaptive system | 17 |
control room | 17 |
sensor layout | 17 |
record systems | 17 |
compatibility testing | 17 |
resonance energy | 17 |
mds patients | 17 |
financial markets | 17 |
edge computing | 17 |
vitro studies | 17 |
low birth | 17 |
also shown | 17 |
secondary structure | 17 |
two distinct | 17 |
wastewater treatment | 17 |
outdoor farming | 17 |
potential impact | 17 |
research interests | 17 |
ten years | 17 |
system functions | 17 |
nasal mucosa | 17 |
product formation | 17 |
genetically engineered | 17 |
multiple myeloma | 17 |
negative bacteria | 17 |
based health | 17 |
new donors | 17 |
fi nding | 17 |
rh phenotype | 17 |
nitrogen sources | 17 |
infected persons | 17 |
mouse model | 17 |
integrated microfluidic | 17 |
positive direct | 16 |
helmet system | 16 |
system antibodies | 16 |
internal controls | 16 |
resource allocation | 16 |
cardiac diseases | 16 |
nutrient solution | 16 |
capping group | 16 |
security experts | 16 |
cyber physical | 16 |
based analysis | 16 |
cancer therapy | 16 |
virus transmission | 16 |
natural products | 16 |
controlled trials | 16 |
one sample | 16 |
organic compounds | 16 |
human gut | 16 |
colorectal cancer | 16 |
hcv nat | 16 |
unit operations | 16 |
financial support | 16 |
wireless sensor | 16 |
increased significantly | 16 |
cost per | 16 |
level rise | 16 |
reducing food | 16 |
recombinant human | 16 |
repeat testing | 16 |
office buildings | 16 |
transfusion purpura | 16 |
high number | 16 |
healthcare workers | 16 |
main focus | 16 |
will decrease | 16 |
various forms | 16 |
volunteer blood | 16 |
new drug | 16 |
found positive | 16 |
electrical impedance | 16 |
security issues | 16 |
also developed | 16 |
vox sang | 16 |
transfusion history | 16 |
objective function | 16 |
nonlinear dynamics | 16 |
exponential growth | 16 |
social determinants | 16 |
market forces | 16 |
external quality | 16 |
evidence based | 16 |
older adults | 16 |
table summarizes | 16 |
zn acoh | 16 |
negative consequences | 16 |
political system | 16 |
cross blood | 16 |
months post | 16 |
acoh redox | 16 |
better results | 16 |
wet markets | 16 |
open systems | 16 |
fog node | 16 |
hierarchical network | 16 |
kidney disease | 16 |
effective theories | 16 |
experimental design | 16 |
data available | 16 |
platelet specific | 16 |
cell concentrate | 16 |
within weeks | 16 |
three days | 16 |
medical doctors | 16 |
controlled trial | 16 |
surveillance data | 16 |
will reduce | 16 |
west african | 16 |
common practice | 16 |
dithiothreitol redox | 16 |
weather conditions | 16 |
general anesthesia | 16 |
samples per | 16 |
receptor binding | 16 |
platelet collection | 16 |
findings suggest | 16 |
information society | 16 |
cost effective | 16 |
chronic care | 16 |
simulation time | 16 |
tracing service | 16 |
disease burden | 16 |
many patients | 16 |
personal protective | 16 |
remote monitoring | 16 |
total population | 16 |
prng seed | 16 |
one system | 16 |
system behavior | 16 |
structural features | 16 |
receive blood | 16 |
ethanol production | 16 |
multiply transfused | 16 |
dominated solutions | 16 |
becoming increasingly | 16 |
common sense | 16 |
light nir | 16 |
morpholine ph | 16 |
reachability analysis | 16 |
bsa enzyme | 16 |
centrifugal microfluidic | 16 |
plasmin enzyme | 16 |
enzyme production | 16 |
positive effects | 16 |
signaling pathways | 16 |
graft versus | 16 |
personal relationships | 16 |
possible solution | 16 |
mobile devices | 16 |
problem solving | 16 |
percolation threshold | 16 |
unmanned aerial | 16 |
genetic analysis | 16 |
million inhabitants | 16 |
studies comparing | 16 |
pcr products | 16 |
renal failure | 16 |
calculated using | 16 |
biogeochemical cycles | 16 |
remained stable | 16 |
high rates | 16 |
will enable | 16 |
service layer | 16 |
parking system | 16 |
university medical | 16 |
medical applications | 16 |
th week | 16 |
air dehumidification | 16 |
security requirements | 16 |
piperidine morpholine | 16 |
full potential | 16 |
glucuronidase enzyme | 16 |
coronary heart | 16 |
first months | 16 |
two separate | 16 |
life years | 16 |
common diseases | 16 |
fresh platelets | 16 |
much attention | 16 |
mg micromotors | 16 |
dna rna | 16 |
important issue | 16 |
human igg | 16 |
procedures performed | 16 |
blot analysis | 16 |
health risks | 16 |
threat agents | 16 |
tumor tissues | 16 |
computer systems | 16 |
angular velocity | 16 |
increased susceptibility | 16 |
information infrastructure | 16 |
improve quality | 16 |
primary principles | 16 |
copy number | 16 |
regular blood | 16 |
clinical conditions | 16 |
thiols redox | 16 |
financial interests | 16 |
gpib expression | 16 |
step towards | 16 |
general hospitals | 16 |
network models | 16 |
sierra leone | 16 |
ice sheet | 16 |
laboratory results | 16 |
primer pairs | 16 |
rare red | 16 |
data transmission | 16 |
antigen expression | 16 |
food products | 16 |
working hours | 16 |
female patient | 16 |
hand side | 16 |
transfusion chain | 16 |
individual patients | 16 |
attitude towards | 16 |
energy modeling | 16 |
affinity chromatography | 16 |
become available | 16 |
unintended consequences | 16 |
emergency situations | 16 |
clinical course | 16 |
home environment | 16 |
tube testing | 16 |
different aspects | 16 |
regular basis | 16 |
polymers based | 16 |
system concerns | 16 |
blood plasma | 16 |
water resources | 16 |
southern oscillation | 16 |
using pcr | 16 |
coumarin derivatives | 16 |
ester carbamate | 16 |
data store | 16 |
software architecture | 16 |
sequence analysis | 16 |
behavior change | 16 |
new blood | 16 |
investigated using | 16 |
external controls | 16 |
across multiple | 16 |
cell salvage | 16 |
three blood | 16 |
thermal cycling | 16 |
automated cell | 16 |
physical attacks | 16 |
raw material | 16 |
one rbc | 16 |
production quantity | 16 |
mean field | 16 |
laboratory staff | 16 |
energy transition | 16 |
people will | 16 |
musculoskeletal disorders | 16 |
organic matter | 16 |
hbsag negative | 16 |
time scales | 16 |
signal strength | 16 |
lymphoid cells | 16 |
culture media | 16 |
care organizations | 16 |
treated red | 16 |
giving rise | 16 |
culture systems | 16 |
energy demand | 16 |
statistical methods | 16 |
medical error | 16 |
antibodies anti | 16 |
positive impact | 16 |
ph responsive | 16 |
homomorphic encryption | 16 |
within days | 16 |
less likely | 16 |
protective equipment | 16 |
triblock copolymers | 16 |
commons license | 16 |
using standard | 15 |
contract location | 15 |
member states | 15 |
patient identification | 15 |
information provided | 15 |
recent research | 15 |
comparing ffp | 15 |
cyber security | 15 |
linear algebraic | 15 |
relative birth | 15 |
may reduce | 15 |
redox plasmin | 15 |
cloud computing | 15 |
particular interest | 15 |
size expansion | 15 |
hbsag positive | 15 |
detected using | 15 |
data protection | 15 |
rhd immunization | 15 |
control unit | 15 |
sciences authority | 15 |
central role | 15 |
ab titers | 15 |
fresenius hemocare | 15 |
factor xiii | 15 |
oral disease | 15 |
national haemovigilance | 15 |
will facilitate | 15 |
duct system | 15 |
expression level | 15 |
results revealed | 15 |
temperature control | 15 |
dual stimuli | 15 |
qualitatively different | 15 |
transport system | 15 |
randomly selected | 15 |
computational model | 15 |
springer nature | 15 |
several different | 15 |
dilution rate | 15 |
recent developments | 15 |
look like | 15 |
important part | 15 |